Association between uricemia and metabolic syndrome in a hospital center in Corrientes

Authors

  • Silvia Beatriz Gorbán de Lapertosa Faculty of Medicine, Northeast National University (UNNE), Corrientes, Argentina
  • Claudia Alejandra Miño Hospital Angela I. de Llano, School of Dentistry and School of Medicine, National University of the Northeast (UNNE), Corrientes, Argentina
  • Isabel Cristina Llanos Hospital Ángela I. de Llano, Faculty of Dentistry, Faculty of Medicine (UNNE), National Northeast University (UNNE), Corrientes, Argentina
  • Claudio Daniel González Faculty of Medicine, Austral University and Favaloro University. University Institute of the Center for Medical Education and Clinical Research "Norberto Quirno" (CEMIC), Autonomous City of Buenos Aires (CABA), Argentina

DOI:

https://doi.org/10.47196/diab.v56i3.524

Keywords:

metabolic syndrome, uric acid, hyperuricemia

Abstract

Introduction: in recent years, numerous scientific evidence suggest that hyperuricemia may play a role in the development of metabolic syndrome (MS). Some studies have explored the association between uricemia and the presence of MS. However, it remains unclear whether high uric acid levels are causally related to the development of MS. Moreover, there are few studies on the presence of metabolic syndrome and its relationship with uric acid (UA) levels in the city of Corrientes, Argentina.

Objectives: to determine the relationship between serum UA levels and the parameters that define MS in patients attending the outpatient clinic of Medical Clinic and General Medicine of the Ángela I. de Llano Hospital, Corrientes.

Material and methods: quantitative, descriptive, cross-sectional study. A questionnaire was applied to collect data such as age, sex, medications used, and smoking history. Participants' weight, height, waist circumference and body mass index were measured. Basal glucose, oral glucose tolerance curve, uric acid, triglycerides, HDL cholesterol, and systolic and diastolic blood pressure were determined. The presence of MS was defined according to the modified National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria.

Results: a total of 435 patients over 18 years of age were included: 312 (72%) women and 123 (28) men. Fifty-eight percent of the population met the NCEP-ATP III criteria for MS (60% females and 52% males). Seventy-five percent of the population had hyperuricemia and MS. In this study the presence of MS was significantly associated with uricemia values OR:1.5 (95%CI:1.3-1.8). The association is statistically significant.

Conclusions: The results show that the increase in the frequency of the components of MS, goes in direct relation with the increase in serum UA levels and that the cut-off value for this association is 4 mg/dl. Hence the importance of considering the determination of serum UA levels as a possible predictor of MS.

Author Biographies

Silvia Beatriz Gorbán de Lapertosa, Faculty of Medicine, Northeast National University (UNNE), Corrientes, Argentina

Professor of Nutrition and Health Education, Bachelor's Degree in Kinesiology and Physiatry

 

Claudia Alejandra Miño, Hospital Angela I. de Llano, School of Dentistry and School of Medicine, National University of the Northeast (UNNE), Corrientes, Argentina

Biochemistry, Master in Research in Health Sciences; Head of Practical Work, Biochemistry subject

Isabel Cristina Llanos, Hospital Ángela I. de Llano, Faculty of Dentistry, Faculty of Medicine (UNNE), National Northeast University (UNNE), Corrientes, Argentina

Biochemistry, Master in Research in Health Sciences; Head of Practical Work, Biochemistry subject

Claudio Daniel González, Faculty of Medicine, Austral University and Favaloro University. University Institute of the Center for Medical Education and Clinical Research "Norberto Quirno" (CEMIC), Autonomous City of Buenos Aires (CABA), Argentina

Professor of Pharmacology

References

I. Barrera-Cruz A, Rodríguez-González A, Molina-Ayala MA. Escenario actual de la obesidad en México. Rev Med Inst Mex Seguro Soc 2013;51(3):292-99.

II. López-Suárez A, Elvira-González J, Bascuñana-Quirell A, Rosal-Obrador J, Michán-Doña A, Escribano-Serrano J, et al. Serum urate levels and urinary acid excretion in subjects with metabolic síndrome. Med Clin (Barc) 2006;126(9):321-324.

III. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Current Hypertension Reports 2013;15(3):175-181.

IV. Reyes JAE, Navarro J, Cruz IM, Castro DLJ, Landgrave GJ, Narváez PC, Landgrave GI, Oregón LA, Espinosa LFR. Prevalencia del síndrome metabólico en relación con las concentraciones de ácido úrico. Medicina Interna de México 2009;25(4):278-284.

V. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-1958. Doi: 10.1093/eurheartj/ehw152.

VI. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic curve. Radiology1982;143(1):29-36.

VII. Cerda J, Cifuentes L. Uso de curvas ROC en investigación clínica. Aspectos teórico prácticos. Rev Chil Infectol 2012 Abr;29(2):138-141.

VIII. Altman DG, Gardner M. Diagnostics tests. In: Altman DG, Machin D, Trevor NB, Gardner S. (Eds.). Statistics with confidence: confidence intervals and statistics guidelines. 2º Ed. London: John Wiley & Sons; 2000. p. 105-19.

IX. Yamasaki T, Tomita K. Relationship between hyperuricemia and metabolic syndrome. Nippon Rinsho 2008 Apr;66(4):766-70.

X. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, Yazici M, Keles I. Serum uric acid is a determinant of metabolic syndrome in a population-based estudy. Am J Hypertens 2006 Oct;19(10):1055-62.

XI. 4° Encuesta Nacional de Factores de Riesgo: resultados preliminares. 1º Ed. Ciudad Autónoma de Buenos Aires: Instituto Nacional de Estadística y Censos - INDEC; Secretaría de Gobierno de Salud, 2019. ISBN 978-950-896-542-4. Disponible en https://www.indec.gob.ar/ftp/cuadros/publicaciones/enfr_2018_resultados_definitivos.pdf.

XII. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. CMAJ 2006;174(6):801-809.

XIII. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356- 59.

XIV. Martínez-Larrad MT, Fernández-Pérez C, Sánchez JL, López A, Fernández-Álvarez J, Riviriego J, et al. Prevalencia del síndrome metabólico (criterios ATP III). Estudio de base poblacional en áreas rural y urbana de la provincia de Segovia. Med Clin (Barc) 2005;125:481-6.

XV. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, Gabriel R, Williams K, Gómez-Gerique JA, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003;11:1480-7.

XVI. Álvarez-León EE, Ribas-Barba L, Serra-Majem L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin 2003;120:172-4.

XVII. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Valls J, Carmena R. Abdominal obesity, insulin-resistance, and metabolic syndrome in a southern European population. Eur J Intern Med 2003;14:101-6.

XVIII. Braguinsky J. Síndrome metabólico ¿enfermedad metabólica? Una mirada abierta desde la clínica. 2º Edición. Argentina: Acindes; 2006.p.1-92.

XIX. Díaz A, Espeche WG, March CE, Flores R, Parodi R, Genesio MA, Sabio R, Poppe S. Prevalencia del síndrome metabólico en Argentina en los últimos 25 años. Revisión sistemática de estudios observacionales poblacionales. Hipertensión y Riesgo Vascular 2018;35 (2):64-69

XX. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;237(3):356-359. doi: 10.1001/jama.287.3.356.

XXI. Schettini C, Schewdt E, Moreira V, Mogdasy C, Chávez L, Bianchi M, et al. Prevalencia del síndrome metabólico en una población adulta. Rev Urug Cardiol 2004;19:19-28.

XXII. Sui X, Church T, Meriwether R, et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008;57:845-852.

XXIII. Al-Arfaj AS. Hyperuricemia in Saudi Arabia. Rheumatol Int 2001;20:61-64.

XXIV. Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res 2006;37:883-889.

XXV. Lai SW, Tan CK. Epidemiology of hyperuricemia in the elderly. Yale J Biol Med 2001; 74:151-7.

XXVI. López-Suárez A, Elvira-González J, Bascuñana-Quirell A, Rosal-Obrador J, Michán-Doña A, Escribano-Serrano J, et al. FERUM urate levels and urinary acid excretion in subjects with metabolic síndrome. Med Clin (Barc) 2006;126(9):321- 4.

XXVII. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120:442-7.

XXVIII. Bonakdaran S, Kharaqani B. Association of serum uric acid and metabolic syndrome in type 2 diabetes. Curr Diabetes Rev 2014 Mar;10(2):113-7.

XXIX. Lee SJ, Oh BK, Sung Ki-Chul. Uric acid and cardiometabolic diseases. Clinical Hypertension 2020; 26:(13) 1-7.

Downloads

Published

2022-12-01

How to Cite

Gorbán de Lapertosa, S. B., Miño, C. A., Llanos, I. C., & González, C. D. (2022). Association between uricemia and metabolic syndrome in a hospital center in Corrientes. Journal of the Argentine Society of Diabetes, 56(3), 83–92. https://doi.org/10.47196/diab.v56i3.524

Issue

Vol. 56 No. 3 (2022): September/December 2022

Section

Original article

License

Copyright (c) 2022 in the name of the authors. Reproduction rights: Argentine Diabetes Society.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Most read articles by the same author(s)

<< < 1 2 3